The renin-angiotensin system in the year 2000

Journal of Human Hypertension

Volumn 14, Issue 10-11, 2000, Pages 649-666

  Nicholls, M G ^a   Robertson, J I S ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b Elmbank   (United Kingdom)

Author keywords

Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRILAT; LOSARTAN; NIFEDIPINE; RAMIPRIL; RENIN INHIBITOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; ENDOTHELIUM; GENETIC ASSOCIATION; HEART FAILURE; HUMAN; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEPHRECTOMY; NONHUMAN; PHYLOGENY; PNEUMONIA; PREGNANCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW;

EID: 0033760457     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001056     Document Type: Review

References (265)

1. Niere und Kreislauf
2. Renin and angiotensin: A historical view
3. Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia
4. Some observations on renin, a pressor substance contained in normal kidney, together with a method for its biological assay
5. Activation of renin by blood colloids
6. Hypertensin: The substance causing renal hypertension
7. La fonction endocrine des arterioles renales: Son role dans la pathogenie de l'hypertension arterielle
8. Hypertension produced in the rabbit by long-continued infusion of renin
9. A slowly developing pressor response to small concentrations of angiotensin
10. The fast and the slowly developing pressor effect of angiotensin II
11. The chemistry of renin substrate
12. Amino acid sequence in a hypertensin
13. The amino acid sequence of hypertensin II
14. New synthesis in the peptide field
15. Renin und Hypertensin: Physiologische oder pathologische Wirkstoffe?
16. Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism
17. Adrenocortical function in essential hypertension
18. Hypotensive agents and pressor substances: The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man
19. Stimulation of aldosterone secretion by angiotensin II
20. Intrarenal and circulating angiotensin II and renal function
21. Influence of sodium loading and sodium depletion on plasma renin in man
22. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man
23. Angiotensin II/aldosterone dose-response curves in the dog: Effect of changes in sodium balance
24. The juxtaglomerular cells in man and their relationship to the level of plasma sodium and to the zona glomeruloswa of the adrenal cortex
25. Renin and angiotensin. A survey of some aspects
26. The measurement of renin
27. New procedures for measurement of human plasma angiotensin and renin activity levels
28. Radio-immunoassay determination of plasma-renin activity
29. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects
30. The estimation of renin in plasma by an enzyme kinetic technique
31. The estimation of renin in human plasma
32. Inactive renin in human plasma
33. An inactive renin in human plasma
34. An inactive higher-molecule-weight renin in normal subjects and hypertensive patients
35. Inactive renin: An attempt at a perspective
36. Plasma prorenin - Physiological and biochemical characteristics
37. Estimation of angiotensin I and II in the human circulation by radioimmunoassay
38. Angiotensin II, aldosterone and arterial pressure. A quantitative approach
39. A qualitative and quantitative study of renin in the different layers of the rabbit uterus
40. Extrarenal renin systems: Salivary glands
41. Cardiac, vascular, and intrarenal renin-angiotensin systems in normal physiology and disease
42. The adrenal cortical renin-angiotensin system
43. The ovary
44. Renin, uterus and amniotic fluid
45. Renin in the testis and epididymis
46. Identification and quantification of renin and prorenin in the bovine eye
47. Extrarenal renin systems: The brain
48. Beta adrenoceptor blockers and the renin-angiotensin system
49. Angiotensin-converting enzyme inhibitors
50. Angiotensin antagonists
51. The use of blocking agents to define the function of the renin-angiotensin system. Volhard lecture
52. Drugs affecting the renin-angiotensin-aldosterone system: Use of angiotensin inhibitors
53. Slow rise and diurnal change of blood pressure with saralasin and angiotensin II in rats
54. Selective angiotensin II type 1 receptor antagonists; History and outlook
55. Future prospects of angiotensin II antagonists
56. Renin inhibitors
57. Discovery and development of renin inhibitors
58. Renin: Purification, structure, and function
59. Interrelations between renin and atrial natriuretic factor
60. Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue
61. Renin secretion: Control, pathways, and glycosylation
62. Role of nitric oxide in the control of renin secretion
63. Effects of Auriculin (Atrial Natriuretic Factor) on blood pressure, renal function, and the renin-aldosterone system in dogs
64. Atrial natriuretic peptide blocks renin response to renal hypotension
65. Atrial natriuretic peptide inhibits postural release of renin and vasopressin in humans
66. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations
67. Stimulation of the renin-angiotensin system by endothelin subtype A receptor blockade in conscious dogs
68. Andrenomedulin stimulates renin release and renin mRNA in mouse juxtaglomerular granular cells
69. Angiotensin II receptors
70. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system
71. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men
72. Nephrigenesis and angiotensin II receptor subtypes gene expression in the fetal lamb
73. An intact renin-angiotensin system is a prerequisite for normal renal development
74. The renin-angiotensin system in cardiovascular physiology and disease: New insights from molecular studies
75. Phylogeny and comparative physiology of the renin-angiotensin system
76. Conclusions: The future
77. The pathophysiology of prorenin
78. The greater renin system: Its prorenin-directed vasodilator limb. Relevance to diabetes mellitus, pregnancy, and hypertension
79. Biochemical aspects of the angiotensins
80. Angiotensin II depressor action in the conscious rabbit is blocked by losartan but not PD 123319
81. The other angiotensins
82. Renin and the pathophysiology of renovascular hypertension
83. Renin, angiotensin, Goldblatt hypertension and hypertension produced by sodium restriction
84. Renin in cardiac failure
85. The renin-angiotensin system post-myocardial infarction and in heart failure
86. Renin relationships in congestive cardiac failure, treated and untreated
87. Total body electrolyte composition in patients with heart failure: A comparison with normal subjects and patients with untreated hypertension
88. Angiotensin-converting enzyme inhibitors in the treatment of heart failure
89. Angiotensin-converting enzyme inhibitors in heart failure
90. Angiotensin receptor antagonists in the treatment of chronic heart failure
91. ACE inhibitors in and after myocardial infarction
92. Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension
93. Side effects associated with inhibitors of angiotensin-converting enzyme
94. Angiotensin II - Possible adverse effects on arteries, heart, brain and kidney: Experimental, clinical, and epidemiological evidence
95. Trophic effects of angiotensin on blood vessels and heart
96. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
97. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study
98. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
99. Outcome differences between ACE inhibitor and calcium channel blocker treated hypertensive patients. Abstract No. 14
100. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
101. Prevention of stroke and cancer: Could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?
102. Reduction of risk of pneumonia with use of angiotensin I converting enzyme inhibitors in elderly patients
103. Angiotensin II receptor antagonists
104. Additive effects of losartan and enalapril on blood pressure and plasma active renin
105. 2 receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries
106. 2 receptor stimulation enhances antihypertensive rats
107. The angiotensin type 2 receptor: Variations on an enigmatic theme
108. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function
109. Evaluation of organ damage in hypertension
110. Microalbuminuria and progressive renal disease
111. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension?
112. Predictors of hypertensive nephropathy: Results of a 6-year follow-up study in essential hypertension
113. Angiotensin-converting enzyme inhibitors in diabetes mellitus
114. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease
115. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function
116. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects
117. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine
118. Titrating for antiproteinuric effect: The clue to renoprotection?
119. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function
120. Angiotensin-converting enzyme inhibitors in diabetes: Renal effects
121. Angiotensin-converting enzyme inhibitors in diabetes: Extrarenal effects
122. Prevention of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and the MICRO-HOPE substudy
123. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockade in microalbuminuria
124. Epidemiology of the renin-angiotensin system in hypertension
125. Molecular biology of the angiotensin I converting enzyme. I: Biochemistry and structure of the gene
126. Genetic aspects of the renin-angiotensin system
127. Molecular biology of renin. I: Gene and protein structure, synthesis and processing
128. Identification of essential hypertension genes
129. Finding genes that cause human hypertension
130. Beyond genetic markers: Hypertension genes
131. Renin gene restriction fragment length polymorphisms in a Japanese family with a high incidence of essential hypertension
132. Renin and atrial natriuretic peptide restriction fragment length polymorphisms: Association with ethnicity and blood pressure
133. Restriction fragment length polymorphisms of a human renin gene: Association study with a family history of hypertension
134. Angiotensinogen: Biochemical aspects
135. Regulation and function of angiotensinogen gene expression
136. Molecular basis of human hypertension: Role of angiotensinogen
137. Angiotensinogen in human essential hypertension
138. Linkage of the angiotensinogen gene to essential hypertension
139. 235→Thr variant in blood pressure and other cardiovascular risk factors in two Japanese populations
140. Angiotensinogen as a risk factor for essential hypertension in Japan
141. Association analysis of a polymorphism of the angiotensinogen gene with essential hypertension in Japanese
142. Molecular variants of the angiotensinogen gene and hypertension in a Japanese population
143. M235→T polymorphism of the angiotensinogen gene predicts hypertension in the elderly
144. Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset
145. Molecular variant M235T of the angiotensinogen gene is associated with essential hypertension in Taiwanese
146. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort
147. Renin-angiotensin system polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition
148. A molecular variant of angiotensinogen associated with preeclampsia
149. Enhanced prediction of myocardial infarction in Japanese by combined genotype analysis
150. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease
151. Angiotensinogen genotype, sodium restriction, weight loss, and prevention of hypertension
152. Relationship between the M235T and G(-6)A polymorphisms of the angiotensinogen gene
153. Angiotensinogen and blood pressure among blacks: Findings from a community survey in Jamaica
154. Angiotensinogen gene in human hypertension: Lack of an association of the 235T allele among African Americans
155. Linkage of the angiotensinogen gene locus to human hypertension in African Caribbeans
156. Blood pressure and the M235T polymorphism of the angiotensinogen gene
157. Genetic variants of the renin-angiotensin system and ambulatory blood pressure in essential hypertension
158. Variation of the M235T locus of the angiotensinogen gene and essential hypertension: A population-based case-control study from Rochester, Minnesota
159. Angiotensinogen Met 235→Thr polymorphism in a London normotensive and hypertensive black and white population
160. Evaluation of the angiotensinogen locus in human essential hypertension: A European study
161. Genetic studies of the renin-angiotensin system in arterial hypertension associated with non-insulin dependent diabetes mellitus
162. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of renin-angiotensin system genes
163. Linkage of the angiotensinogen gene to essential hypertension
164. Association between the angiotensinogen 235-T variant and essential hypertension in whites
165. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme
166. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
167. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease
168. Angiotensin I converting enzyme gene polymorphism and coronary heart disease
169. The angiotensin converting enzyme and blood pressure in Jamaicans
170. Distribution of plasma angiotensin I-converting enzyme levels in healthy men: Relationship to environmental and hormonal parameters
171. Association of a polymorphism of the angiotensin I converting enzyme gene with essential hypertension
172. Different frequencies of angiotensin-converting enzyme genotype in older hypertensive individuals
173. Angiotensin-converting enzyme polymorphism and essential hypertension
174. Angiotensin I converting enzyme gene polymorphism in Chinese patients with hypertension
175. Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension
176. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension
177. The angiotensin I converting enzyme gene and predisposition to high blood pressure
178. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch hypertension and offspring study
179. Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population
180. Angiotensin I converting enzyme (ACE) gene polymorphism and essential hypertension in Japan: Ethnic difference of ACE genotype
181. Angiotensin converting enzyme gene polymorphism in essential hypertension based on ambulatory blood pressure monitoring
182. I/D polymorphism of the angiotensin-converting enzyme gene does not predict isolated systolic or systolic-diastolic hypertension in the elderly
183. Angiotensin converting enzyme gene I/D polymorphism, blood pressure, and the reninangiotensin system in Caucasian and Afro-Caribbean peoples
184. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
185. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy
186. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
187. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden death
188. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy
189. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction
190. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction
191. Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives
192. Angiotensin-converting enzyme gene polymorphism in haemodialysis patients
193. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
194. Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction
195. Polymorphism of the apolipoprotein and angiotensin converting enzyme genes in young North Karelian patients with coronary heart disease
196. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease
197. Angiotensin-converting enzyme (ACE) gene polymorphisms, serum ACE activity, and blood pressure in a Spanish-Mediterranean population
198. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls
199. Angiotensin converting enzyme genotypes and disease: Conflicting results leave the picture unclear
200. Angiotensin I-converting enzyme genotypes and angiotensin II receptors: Response to therapy
201. Angiotensin II receptor gene polymorphisms and risk of myocardial infarction
202. New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: The ECTIM study
203. 1166 polymorphism: Relationships with blood pressure and cardiovascular structure
204. Two point mutations within the adducin genes are involved in blood pressure variation
205. The α-adducin polymorphism: A paradigm to analyse the genetics of primary hypertension
206. Association of the a-adducin locus with essential hypertension
207. Genetics of renal mechanisms of primary hypertension: The role of adducin
208. Genetic determinations and renal mechanisms in essential hypertension
209. Polymorphisms of a-adducin and salt sensitivity in patients with essential hypertension
210. Polymorphism of α-adducin and hypertension
211. Lack of association between the a-adducin locus and essential hypertension in the Japanese population
212. Human α-adducin gene, blood pressure, and sodium metabolism
213. Role of the Gly 460 Trp polymorphism of the α-adducin gene in primary hypertension in Scandinavians
214. Association of the a-adducin polymorphism with blood pressure and risk of myocardial infarction
215. The renin system in fertility and normal human pregnancy
216. The renin-angiotensin-aldosterone system in hypertension in human pregnancy
217. The epidemiology of plasma renin
218. Plasma renin activity and ischemic heart disease
219. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
220. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men
221. Dietary sodium intake and mortality: The National Health and Nutrition Survey (NHANES I)
222. Renin-sodium profile and the risk of myocardial infarction in patients with hypertension
223. Low urinary sodium and myocardial infarction
224. Sodium intake and mortality
225. Dietary sodium intake and mortality: NHANES
226. ACE inhibitors and mortality at the Glasgow Blood Pressure Clinic
227. Renin-sodium profile and the risk of myocardial infarction in patients with hypertension
228. Renin-sodium profile and the risk of myocardial infarction in patients with hypertension
229. Low urinary sodium and myocardial infarction
230. Low urinary sodium and myocardial infarction
231. Sodium intake and mortality
232. Sodium intake and mortality
233. Sodium intake and mortality
234. Dietary sodium intake and mortality: NHANES
235. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: A meta-analysis
236. Existence of renin in the endothelium of human artery
237. Biochemistry of angiotensin I-converting enzyme
238. Endothelium-derived mediators and the renin-angiotensin system
239. Endothelium-1 augments pressor response to angiotensin II infusion in rats
240. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade
241. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats
242. Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo
243. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients
244. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin
245. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin
246. Effect of captopril and enalapril on endothelial function in hypertensive patients
247. Role of the renin-angiotensin system in neointima formation after injury in rabbits
248. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation
249. Angiotensin II stimulates synthesis of endothelial nitric oxide synthase
250. Effect of nitric oxide on DNA replication induced by angiotensin II in rat cardiac fibroblasts
251. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atheroslerotic lesions
252. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta
253. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits
254. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
255. Angiotensin II generation by non-ACE pathways in human resistance arteries
256. 1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block
257. Continuation of initial antihypertensive medication after 1 year of therapy
258. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
259. Losartan Heart Failure Survival Study - ELITE II
260. Concluding remarks, International Symposium on Angiotensin, Sodium and Hypertension, Quebec, Canada, October 11-14, 1963
261. An international collaborative study of renin assay: Establishment of the international reference preparation of human renin
262. Renin and angiotensin standards
263. Appendix II: Standardization and standards